Study to Determine the Safety and Efficacy of Ribociclib in Combination With Hormone Therapy and Hypofractionated Radiotherapy in Breast Cancer, With Positive Hormone Receptors and Negative HER2 Status, in Newly Diagnosed, Not Immediately Operable Elderly Patient (CALHYS)

NCT05664893 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Sponsor decision due to recruitment default

Conditions

HER2 Negative Breast Cancer Not Immediately Operated

Interventions

DRUG: Ribociclib Oral Tablet

Sponsor

Centre Antoine Lacassagne